share_log

BMO Capital Initiates Coverage On IGM Biosciences With Outperform Rating, Announces Price Target of $21

Benzinga ·  Dec 6, 2024 18:52  · Ratings

BMO Capital analyst Etzer Darout initiates coverage on IGM Biosciences (NASDAQ:IGMS) with a Outperform rating and announces Price Target of $21.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment